Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the antitumor efficacy, as determined by the objective response rate (ORR) of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, in patients with relapsed or refractory classical HL who are considered to be not suitable for SCT or multiagent chemotherapy
Inclusion criteria
- relapsed or refractory Hodgkin Lymphoma